In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 10, 2006, Pages 3496-3498

  Clancy, Cornelius J ^a,b   Staley, Benjamin ^c   Nguyen, M Hong ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; BLOOD; CANDIDA; CANDIDIASIS; CHEMOPREVENTION; FLUCONAZOLE; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33749509033     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00741-06     Document Type: Article

References (20)

1. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snydman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
2. Girmenia, C., P. Martino, F. De Bernardis, G. Gentile, M. Boccanera, M. Monaco, G. Antonucci, and A. Cassone. 1996. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin. Infect. Dis. 23:506-514.
3. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, D. J. Friedman, et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
4. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
5. Marr, K. A., T. C. White, J. A. van Burik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
6. Mori, T., M. Matsumura, Y. Kanamaru, S. Miyano, T. Hishikawa, S. Irie, K. Oshimi, T. Saikawa, and T. Oguri. 1997. Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to agents during therapy. Clin. Infect. Dis. 25:1470-1471.
7. Myoken, Y., T. Kyo, M. Fujihara, T. Sugata, and Y. Mikami. 2004. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica 89:378-380.
8. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
9. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
10. Nucci, M., and A. L. Colombo. 2002. Risk factors for breakthrough candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 21:209-211.
11. Pelz, R. K., C. W. Hendrix, S. M. Swoboda, M. Diener-West, W. G. Merz, J. Hammond, and P. A. Lipsett. 2001. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233:542-548.
12. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
13. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, intraconzale, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24:248-249.
14. Safdar, A., F. van Rhee, J. P. Henslee-Downey, S. Singhal, and J. Mehta. 2001. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 28:873-878.
15. Shorr, A. F., K. Chung, W. L. Jackson, P. E. Waterman, and M. H. Kollef. 2005. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med. 33:1928-1935.
16. Slavin, M. A., B. Osborne, R. Adams, M. J. Levenstein, H. G. Schoch, A. R. Feldman, J. D. Meyers, and R. A. Bowden. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J. Infect. Dis. 171:1545-1552.
17. Swoboda, S. M., W. G. Merz, and P. A. Lipsetta. 2003. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg. Infect. (Larchmt) 4:345-354.
18. Thomas, J. K., A. Forrest, S. M. Bhavnani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation for factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
19. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
20. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.